These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 10346934)
1. A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides. Hamilton DS; Kavarana MJ; Sharkey EM; Eiseman JL; Creighton DJ J Med Chem; 1999 May; 42(10):1823-7. PubMed ID: 10346934 [TBL] [Abstract][Full Text] [Related]
2. Mechanism-based competitive inhibitors of glyoxalase I: intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serum. Kavarana MJ; Kovaleva EG; Creighton DJ; Wollman MB; Eiseman JL J Med Chem; 1999 Jan; 42(2):221-8. PubMed ID: 9925727 [TBL] [Abstract][Full Text] [Related]
3. Bivalent transition-state analogue inhibitors of human glyoxalase I. Zheng ZB; Creighton DJ Org Lett; 2003 Dec; 5(25):4855-8. PubMed ID: 14653691 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. Sharkey EM; O'Neill HB; Kavarana MJ; Wang H; Creighton DJ; Sentz DL; Eiseman JL Cancer Chemother Pharmacol; 2000; 46(2):156-66. PubMed ID: 10972486 [TBL] [Abstract][Full Text] [Related]
5. N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase i inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities. Zheng ZB; Zhu G; Tak H; Joseph E; Eiseman JL; Creighton DJ Bioconjug Chem; 2005; 16(3):598-607. PubMed ID: 15898727 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of S-(p-bromobenzyl)glutathione diesters in vitro: a structure-activity study. Thornalley PJ; Ladan MJ; Ridgway SJ; Kang Y J Med Chem; 1996 Aug; 39(17):3409-11. PubMed ID: 8765525 [TBL] [Abstract][Full Text] [Related]
7. N,S-bis-fluorenylmethoxycarbonylglutathione: a new, very potent inhibitor of mammalian glyoxalase II. Elia AC; Chyan MK; Principato GB; Giovannini E; Rosi G; Norton SJ Biochem Mol Biol Int; 1995 Apr; 35(4):763-71. PubMed ID: 7627127 [TBL] [Abstract][Full Text] [Related]
8. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092 [TBL] [Abstract][Full Text] [Related]
9. S-(N-aryl-N-hydroxycarbamoyl)glutathione derivatives are tight-binding inhibitors of glyoxalase I and slow substrates for glyoxalase II. Murthy NS; Bakeris T; Kavarana MJ; Hamilton DS; Lan Y; Creighton DJ J Med Chem; 1994 Jul; 37(14):2161-6. PubMed ID: 8035422 [TBL] [Abstract][Full Text] [Related]
10. Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. Kalsi A; Kavarana MJ; Lu T; Whalen DL; Hamilton DS; Creighton DJ J Med Chem; 2000 Oct; 43(21):3981-6. PubMed ID: 11052803 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of glyoxalase I by the enediol mimic S-(N-hydroxy-N-methylcarbamoyl)glutathione. The possible basis of a tumor-selective anticancer strategy. Hamilton DS; Creighton DJ J Biol Chem; 1992 Dec; 267(35):24933-6. PubMed ID: 1459997 [TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of Potent Human Glyoxalase I Inhibitors. Jin T; Zhai J; Liu X; Yue Y; Huang M; Li Z; Ni C; Deng Q; Sang Y; Yao Z; Zhang H; Hu X; Zheng ZB Chem Pharm Bull (Tokyo); 2017 May; 65(5):455-460. PubMed ID: 28320998 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activities of Mannich bases of chalcones and related compounds. Dimmock JR; Kandepu NM; Hetherington M; Quail JW; Pugazhenthi U; Sudom AM; Chamankhah M; Rose P; Pass E; Allen TM; Halleran S; Szydlowski J; Mutus B; Tannous M; Manavathu EK; Myers TG; De Clercq E; Balzarini J J Med Chem; 1998 Mar; 41(7):1014-26. PubMed ID: 9544201 [TBL] [Abstract][Full Text] [Related]
14. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Sakamoto H; Mashima T; Sato S; Hashimoto Y; Yamori T; Tsuruo T Clin Cancer Res; 2001 Aug; 7(8):2513-8. PubMed ID: 11489834 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of glyoxalase I: the first low-nanomolar tight-binding inhibitors. More SS; Vince R J Med Chem; 2009 Aug; 52(15):4650-6. PubMed ID: 19610604 [TBL] [Abstract][Full Text] [Related]
16. Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I. Kamiya D; Uchihata Y; Ichikawa E; Kato K; Umezawa K Bioorg Med Chem Lett; 2005 Feb; 15(4):1111-4. PubMed ID: 15686923 [TBL] [Abstract][Full Text] [Related]
17. A metabolically stable tight-binding transition-state inhibitor of glyoxalase-I. More SS; Vince R Bioorg Med Chem Lett; 2006 Dec; 16(23):6039-42. PubMed ID: 16997560 [TBL] [Abstract][Full Text] [Related]
18. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482 [TBL] [Abstract][Full Text] [Related]
19. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase. Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022 [TBL] [Abstract][Full Text] [Related]
20. Peptide-bond modified glutathione conjugate analogs modulate GSTpi function in GSH-conjugation, drug sensitivity and JNK signaling. Burg D; Riepsaame J; Pont C; Mulder G; van de Water B Biochem Pharmacol; 2006 Jan; 71(3):268-77. PubMed ID: 16337611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]